Answers are grounded in this paper and cite their sources.
Formulation demonstrates improved anticancer efficacy and safety in breast cancer, highlighting the potential for targeted drug repurposing.
The formulation of targeted HA-PF127 micelles overcomes the poor solubility of tofacitinib, provides direct delivery to breast cancer cells and significantly increases the anticancer efficacy, oral bioavailability and safety of the drug.
No takes yet. Share an insight, caveat, or question.
Waghmare et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: